Melanopsin and calbindin immunoreactivity in the inner retina of humans and marmosets AJ Chandra, SCS Lee, U Grünert Visual Neuroscience 36, E009, 2019 | 22 | 2019 |
Thorny ganglion cells in marmoset retina: Morphological and neurochemical characterization with antibodies against calretinin AJ Chandra, SCS Lee, U Grünert Journal of Comparative Neurology 525 (18), 3962-3974, 2017 | 14 | 2017 |
PrevenTing Falls in a high-risk, low vision population through specialist ORientation and Mobility services: the PlaTFORM randomised trial L Keay, L Dillon, K Prentice, K Jakobsen, K Rogers, J Martin, R Ivers, ... Investigative Ophthalmology & Visual Science 63 (7), 1827-1827, 2022 | | 2022 |
Australian Researchers Bridging the Gap AJ Chandra, F Stapleton, R Mani MiVision, 2021 | | 2021 |
Exploring multimorbidity in older Australians with vision impairment: a cross-sectional study L Dillon, A Chandra, K Rogers, L Keay Investigative Ophthalmology & Visual Science 61 (7), 3349-3349, 2020 | | 2020 |
Melanopsin containing ganglion cells and displaced cholinergic amacrine cells in human retina express calbindin. AJ Chandra, SCS Lee, RA Masri, U Grunert Investigative Ophthalmology & Visual Science 59 (9), 5038-5038, 2018 | | 2018 |
Characterisation of Ganglion Cells in Human and Non-Human Primate Retinas AJ Chandra | | 2018 |
Quality of Life Among Older Patients (Age 65+) with Cancer in A University Hospital in India A Chandra, JP Martin Annals of Oncology 23, ix475, 2012 | | 2012 |
PR28 Insurance coverage and haematological malignancies. A study from India A Chandra, J Martin Critical Reviews in Oncology/Hematology, S19, 2012 | | 2012 |
PR53 Tolerability of metronomic chemotherapy in patients with haematological malignancies. A study from India A Chandra, J Martin Critical Reviews in Oncology/Hematology, S28, 2012 | | 2012 |
3610 POSTER Implementation of Insurance Coverage for Cancer Patients a Study A Chandra, JR Martin European Journal of Cancer, S262, 2011 | | 2011 |
3050 Three-day course of granulocyte colony-stimulating factor in patients on chemotherapy for cancer is a safe and cost-effective schedule to maintain dose-intensity: a study … A Chandra, J Martin EJC Supplements 2 (7), 190, 2009 | | 2009 |